Keyword: Alnylam Pharmaceuticals
Facing a major challenge to its RNAi therapy Onpattro, Alnylam afforded itself some breathing room with the approval of its second such therapy only a year later.
Alnylam's lumasiran beat placebo at helping patients clear oxalate from their kidneys, teeing it up for a 2020 filing.
The takeover represents a big bet that a near-approval cholesterol drug will perform better commercially than rival anti-PCSK9 antibodies.
The Medicines Company reported that its PCSK9 drug, inclisiran, cut "bad" LDL cholesterol in patients with plaque buildup in their arteries.
The arrival of the ex-Alnylam VP is one of several changes at the top of Synlogic’s medical, regulatory and financial departments.
Medicines Company showed its siRNA inclisiran has a clean safety profile and is as effective as incumbent drugs sold by Amgen, Regeneron and Sanofi.
Medicines Company is yet to share the efficacy data that will show whether inclisiran can compete but has sought to tackle lingering safety concerns.
Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.
Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.
CEOs weigh in on increasingly large biotech IPOs and an increase in companies going public at earlier stages.
